Study of Interferon Gamma-1b by Injection for the Treatment of Patients With Cystic Fibrosis

Key facts

Sponsor

InterMune

Principal Investigator

Steven Porter, MD

InterMune

Intervention

interferon gamma-1b(drug)

Enrollment

51 enrolled

Eligibility

6 years · All sexes

Timeline

2002 – 2003

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Cystic fibrosis

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT07437105
  Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants
  Vertex Pharmaceuticals Incorporated
• RECRUITINGNANCT07436351
  ACT With CF Self-Help Toolkit
  Thomas Jefferson University
• RECRUITINGNANCT07314229
  Prevalence of Exercise-induced Ventilatory Limitation and Associated Factors in Patients With Cystic Fibrosis Receiving Elexacaftor-Tezacaftor-Ivacaftor
  University Hospital, Lille
• RECRUITINGNCT07083557
  Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)
  Bettina Mittendorfer
• RECRUITINGNCT07369414
  Environmental Reservoirs of Non-tuberculous Mycobacteria in Cystic Fibrosis Households: A Case-control Study of Exposure Risk at Home
  Research Center Borstel
• RECRUITINGNCT07505797
  ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE)
  iSono Health, Inc.
• RECRUITINGPHASE1NCT07283770
  Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants
  Vertex Pharmaceuticals Incorporated
• RECRUITINGNCT07363304
  Impact of Elexacaftor-Tezacaftor-Ivacaftor Treatment on Metabolic, Epigenetic and Fecal Microbiota Profiles in People With Cystic Fibrosis.
  Meyer Children's Hospital IRCCS

See all trials for Cystic fibrosis →